Sichuan Huiyu Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Zhao Ding
Chief executive officer
CN¥1.5m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 14.6yrs |
| CEO ownership | 26.9% |
| Management average tenure | no data |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
Is Sichuan Huiyu Pharmaceutical (SHSE:688553) A Risky Investment?
Jan 02
Sichuan Huiyu Pharmaceutical's (SHSE:688553) Promising Earnings May Rest On Soft Foundations
Nov 02Sichuan Huiyu Pharmaceutical Co., Ltd. (SHSE:688553) Stock Catapults 38% Though Its Price And Business Still Lag The Market
Oct 29Here's Why Sichuan Huiyu Pharmaceutical (SHSE:688553) Can Manage Its Debt Responsibly
Sep 29Sichuan Huiyu Pharmaceutical (SHSE:688553) Has A Pretty Healthy Balance Sheet
Jun 07Sichuan Huiyu Pharmaceutical Co., Ltd.'s (SHSE:688553) 33% Share Price Surge Not Quite Adding Up
Mar 07CEO
Zhao Ding (39 yo)
Dr. Zhao Ding was Non- Executive Director of TYK Medicines, Inc from January 17, 2024 until March 27, 2025 and served as its Director since January 17, 2024 until January 8, 2024. Dr. Ding has experience i...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 14.6yrs | CN¥1.49m | 26.93% CN¥ 1.6b | |
| Director | 2.1yrs | CN¥590.60k | no data | |
| Director | 4.9yrs | no data | no data | |
| Chairman of the Supervisory Board | 3.4yrs | no data | no data | |
| Supervisor | 5.2yrs | no data | no data | |
| Independent Director | 1.3yrs | no data | no data | |
| Director | 2.9yrs | no data | no data | |
| Supervisor | 2.9yrs | no data | no data |
Experienced Board: 688553's board of directors are considered experienced (3.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 19:17 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sichuan Huiyu Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.